Home / Therapies / SGLT-2 Therapy Center

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

CREDENCE Trial Shows Renal and Cardiovascular Protection

3 weeks ago Cardiology, Nephrology, SGLT-2 Therapy Center

Strong results motivate the ADA to update its Standard of Care for patients with diabetes.

Beware: Diuretics Can Increase Risk of Amputations

May 4, 2019 Type 2 Diabetes, SGLT-2 Therapy Center

Adding a SGLT-2 inhibitor which acts as a diuretic can increase the risk.

Canagliflozin Study Stopped Early Due to Positive Results in Reducing CKD, Death and ESRD

Apr 20, 2019 Cardiology, Nephrology, SGLT-2 Therapy Center

Featuring exclusive comments from Dr. George Bakris
Studies are rarely stopped early; when it happens, we should take notice of the results.

GLP-1RA as Add-on Therapy to SGLT-2 Inhibitor

Apr 13, 2019 Articles, SGLT-2 Therapy Center

Combination treatment can help improve glucose levels in patients with elevated HbA1Cs.

Sedentary Behavior During Pregnancy and Neonatal Adiposity

Mar 30, 2019 Obesity, Women's Health, Articles, SGLT-2 Therapy Center

Lifestyle intervention in pregnancy might reduce adverse effects of maternal obesity on neonatal adiposity.

First Dual SGLT-1/2 Inhibitor For Adults With Type 1 Declined Approval

Mar 26, 2019 Articles, SGLT-2 Therapy Center

Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.

John Buse Part 3, SGLT2 Inhibitors Effects On Amputations And Cardiovascular Disease

Feb 12, 2019 ADA 2018, Exclusive Interviews, Videos, SGLT-2 Therapy Center

In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.